Differential effect of endogenous glucagon‐like peptide‐1 on prandial glucose counterregulatory response to hypoglycaemia in humans with and without bariatric surgery
Diabetes, Obesity and Metabolism · 2024
DOI: 10.1111/dom.15570 ↗Kurz gefasst
Fachartikel in der Zeitschrift Diabetes, Obesity and Metabolism, 2024. Verfasst von Henri Honka und 5 weiteren Autor:innen. Beteiligte Einrichtung: Division of Diabetes, University of Texas Health Science Center, San Antonio, Texas, USA. Hauptthemen laut MEDLINE: Blood Glucose, Gastric Bypass, Glucagon-Like Peptide 1, Hypoglycemia. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIDDK NIH HHS, NCATS NIH HHS, Suomen Kulttuurirahasto.
Abstract (Originalsprache)
Aim
To determine the effect of endogenous glucagon‐like peptide 1 (GLP‐1) on prandial counterregulatory response to hypoglycaemia after gastric bypass (GB). Materials and Methods Glucose fluxes, and islet‐cell and gut hormone responses before and after mixed‐meal ingestion, were compared during a hyperinsulinaemic‐hypoglycaemic ( ~ 3.2 mmol/L) clamp with and without a GLP‐1 receptor (GLP‐1R) antagonist exendin‐(9–39) infusion in non‐diabetic patients who had previously undergone GB compared to matched participants who had previously undergone sleeve gastrectomy (SG) and non‐surgical controls.
Results
Exendin‐(9–39) infusion raised prandial endogenous glucose production (EGP) response to insulin‐induced hypoglycaemia in the GB group but had no consistent effect on EGP response among the SG group or non‐surgical controls ( p < 0.05 for interaction). The rates of systemic appearance of ingested glucose or prandial glucose utilization did not differ among the three groups or between studies with and without exendin‐(9–39) infusion. Blockade of GLP‐1R had no effect on insulin secretion or insulin action but enhanced prandial glucagon in all three groups.
Conclusions
These results indicate that impaired post‐meal glucose counterregulatory response to hypoglycaemia after GB is partly mediated by endogenous GLP‐1, highlighting a novel pathogenic mechanism of GLP‐1 in developing hypoglycaemia in this population.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Diabetes, University of Texas Health Science Center, San Antonio, Texas, USA.
- Cardiometabolic Risk Unit, Institute of Clinical Physiology-National Research Council, Pisa, Italy.
- Department of Surgery, University of Texas Health Science Center, San Antonio, Texas, USA.
- South Texas Veteran Health Care System, Audie Murphy Hospital, San Antonio, Texas, USA.
ORCID-Profile: Henri Honka, Amalia Gastaldelli, Ralph DeFronzo
Förderung
- NIDDK NIH HHS
- NCATS NIH HHS
- Suomen Kulttuurirahasto
- National Institute of Diabetes and Digestive and Kidney Diseases
- National Center for Advancing Translational Sciences
Zitieren
APA
Honka, H., Gastaldelli, A., Pezzica, S., Peterson, R., DeFronzo, R., & Salehi, M. (2024). Differential effect of endogenous glucagon‐like peptide‐1 on prandial glucose counterregulatory response to hypoglycaemia in humans with and without bariatric surgery. Diabetes, Obesity and Metabolism. https://doi.org/10.1111/dom.15570
Vancouver
Honka H, Gastaldelli A, Pezzica S, Peterson R, DeFronzo R, Salehi M. Differential effect of endogenous glucagon‐like peptide‐1 on prandial glucose counterregulatory response to hypoglycaemia in humans with and without bariatric surgery. Diabetes, Obesity and Metabolism. 2024. doi:10.1111/dom.15570
BibTeX
@article{Honka2024,
author = {Honka, Henri and Gastaldelli, Amalia and Pezzica, Samantha and Peterson, Richard and DeFronzo, Ralph and Salehi, Marzieh},
title = {Differential effect of endogenous glucagon‐like peptide‐1 on prandial glucose counterregulatory response to hypoglycaemia in humans with and without bariatric surgery},
journal = {Diabetes, Obesity and Metabolism},
year = {2024},
doi = {10.1111/dom.15570}
}
EUVIMED